
Opinion|Videos|July 31, 2023
Closing Thoughts on Enfortumab Vedotin Plus Pembrolizumab in Patients With Advanced Urothelial Carcinoma
Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key data discussed during their conversation with Jonathan E. Rosenberg, MD, on the phase 2 EV-103 trial in metastatic or locally advanced urothelial carcinoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
3
Earlier Cilta-Cel Improves Myeloma Outcomes Via Enhanced Immune Fitness
4
Poll: Vote on the Top Abstracts to Watch at SABCS 2025
5








































